Browse > Article
http://dx.doi.org/10.5483/BMBRep.2022.55.1.133

Immune cell-derived small extracellular vesicles in cancer treatment  

Choi, Sung-Jin (Department of New Biology, DGIST)
Cho, Hanchae (Department of Molecular Medicine, CMRI, Exosome Convergence Research Center (ECRC), School of Medicine, Kyungpook National University)
Yea, Kyungmoo (Department of New Biology, DGIST)
Baek, Moon-Chang (Department of Molecular Medicine, CMRI, Exosome Convergence Research Center (ECRC), School of Medicine, Kyungpook National University)
Publication Information
BMB Reports / v.55, no.1, 2022 , pp. 48-56 More about this Journal
Abstract
Small extracellular vesicles (sEVs) secreted by most cells carry bioactive macromolecules including proteins, lipids, and nucleic acids for intercellular communication. Given that some immune cell-derived sEVs exhibit anti-cancer properties, these sEVs have received scientific attention for the development of novel anti-cancer immunotherapeutic agents. In this paper, we reviewed the latest advances concerning the biological roles of immune cell-derived sEVs for cancer therapy. sEVs derived from immune cells including dendritic cells (DCs), T cells, natural-killer (NK) cells, and macrophages are good candidates for sEV-based cancer therapy. Besides their role of cancer vaccines, DC-shed sEVs activated cytotoxic lymphocytes and killed tumor cells. sEVs isolated from NK cells and chimeric antigen receptor (CAR) T cells exhibited cytotoxicity against cancer cells. sEVs derived from CD8+ T and CD4+ T cells inhibited cancer-associated cells in tumor microenvironment (TME) and activated B cells, respectively. M1-macrophage-derived sEVs induced M2 to M1 repolarization and also created a pro-inflammatory environment. Hence, these sEVs, via mono or combination therapy, could be considered in the treatment of cancer patients in the future. In addition, sEVs derived from cytokine-stimulated immune cells or sEV engineering could improve their anti-tumor potency.
Keywords
Cancer-immune cycle; Cancer immunotherapy; Exosomes; Immune cells; Small extracellular vesicles;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Guo F, Chang CK, Fan HH et al (2008) Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid. J Int Med Res 36, 1342-1353   DOI
2 Romagnoli GG, Zelante BB, Toniolo PA, Migliori IK and Barbuto JA (2014) Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Front Immunol 5, 692   DOI
3 Viaud S, Terme M, Flament C et al (2009) Dendritic cellderived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 4, e4942   DOI
4 Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D and Vujanovic NL (2012) Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 1, 1074-1083   DOI
5 Sobo-Vujanovic A, Munich S and Vujanovic NL (2014) Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells. Cell Immunol 289, 119-127   DOI
6 Choo YW, Kang M, Kim HY et al (2018) M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors. ACS Nano 12, 8977-8993   DOI
7 Escudier B, Dorval T, Chaput N et al (2005) Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med 3, 10   DOI
8 Zhang H, Xie Y, Li W, Chibbar R, Xiong S and Xiang J (2011) CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity. Cell Mol Immunol 8, 23-30   DOI
9 Xie Y, Zhang H, Li W et al (2010) Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity. J Immunol 185, 5268-5278   DOI
10 Zhu L, Kalimuthu S, Oh JM et al (2019) Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming. Biomaterials 190-191, 38-50   DOI
11 Derakhshani A, Vahidian F, Alihasanzadeh M, Mokhtarzadeh A, Lotfi Nezhad P and Baradaran B (2019) Mast cells: a double-edged sword in cancer. Immunol Lett 209, 28-35   DOI
12 Cheng L, Wang Y and Huang L (2017) Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol Ther 25, 1665-1675   DOI
13 Wang P, Wang H, Huang Q et al (2019) Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation. Theranostics 9, 1714-1727   DOI
14 Li Z, Suo B, Long G et al (2020) Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric cancer. Front Cell Dev Biol 8, 572689   DOI
15 Lin Y, Xu J and Lan H (2019) Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol 12, 76   DOI
16 Wu XQ, Dai Y, Yang Y et al (2016) Emerging role of microRNAs in regulating macrophage activation and polarization in immune response and inflammation. Immunology 148, 237-248   DOI
17 Farcas M and Inngjerdingen M (2020) Natural killer cellderived extracellular vesicles in cancer therapy. Scand J Immunol 92, e12938   DOI
18 Busatto S, Vilanilam G, Ticer T et al (2018) Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid. Cells 7, 273   DOI
19 Mathieu M, Martin-Jaular L, Lavieu G and Thery C (2019) Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 21, 9-17   DOI
20 Naslund TI, Gehrmann U, Qazi KR, Karlsson MC and Gabrielsson S (2013) Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol 190, 2712-2719   DOI
21 Segura E, Amigorena S and Thery C (2005) Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis 35, 89-93   DOI
22 Morse MA, Garst J, Osada T et al (2005) A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3, 9   DOI
23 Lu J, Wu J, Xie F et al (2019) CD4(+) T cell-released extracellular vesicles potentiate the efficacy of the HBsAg vaccine by enhancing B cell responses. Adv Sci (Weinh) 6, 1802219   DOI
24 Kalluri R and LeBleu VS (2020) The biology, function, and biomedical applications of exosomes. Science 367, eaau6977   DOI
25 Thery C, Zitvogel L and Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2, 569-579   DOI
26 Urbanelli L, Magini A, Buratta S et al (2013) Signaling pathways in exosomes biogenesis, secretion and fate. Genes (Basel) 4, 152-170   DOI
27 Peters PJ, Borst J, Oorschot V et al (1991) Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med 173, 1099-1109   DOI
28 Li L, Jay SM, Wang Y, Wu SW and Xiao Z (2017) IL-12 stimulates CTLs to secrete exosomes capable of activating bystander CD8(+) T cells. Sci Rep 7, 13365   DOI
29 Seo N, Shirakura Y, Tahara Y et al (2018) Activated CD8(+) T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells. Nat Commun 9, 435   DOI
30 Cai Z, Yang F, Yu L et al (2012) Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol 188, 5954-5961   DOI
31 Paolillo M and Schinelli S (2017) Integrins and exosomes, a dangerous liaison in cancer progression. Cancers (Basel) 9
32 Gao D and Jiang L (2018) Exosomes in cancer therapy: a novel experimental strategy. Am J Cancer Res 8, 2165-2175
33 Ngambenjawong C, Gustafson HH and Pun SH (2017) Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev 114, 206-221   DOI
34 Jong AY, Wu CH, Li J et al (2017) Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles 6, 1294368   DOI
35 Zhu L, Kalimuthu S, Gangadaran P et al (2017) Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics 7, 2732-2745   DOI
36 Neviani P, Wise PM, Murtadha M et al (2019) Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms. Cancer Res 79, 1151-1164   DOI
37 Bernsmeier C, van der Merwe S and Perianin A (2020) Innate immune cells in cirrhosis. J Hepatol 73, 186-201   DOI
38 Kibria G, Ramos EK, Wan Y, Gius DR and Liu H (2018) Exosomes as a drug delivery system in cancer therapy: potential and challenges. Mol Pharm 15, 3625-3633   DOI
39 Segura E, Guerin C, Hogg N, Amigorena S and Thery C (2007) CD8+ dendritic cells use LFA-1 to capture MHC-peptide complexes from exosomes in vivo. J Immunol 179, 1489-1496   DOI
40 Batrakova EV and Kim MS (2015) Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release 219, 396-405   DOI
41 Li Y, Wan YY and Zhu B (2017) Immune cell metabolism in tumor microenvironment. Adv Exp Med Biol 1011, 163-196   DOI
42 Guo S and Deng CX (2018) Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci 14, 2083-2093   DOI
43 Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30, 1-22   DOI
44 McLellan AD (2009) Exosome release by primary B cells. Crit Rev Immunol 29, 203-217   DOI
45 Guan S, Li Q, Liu P, Xuan X and Du Y (2014) Umbilical cord blood-derived dendritic cells loaded with BGC823 tumor antigens and DC-derived exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumor immunity in vitro and in vivo. Cent Eur J Immunol 39, 142-151
46 Lugini L, Cecchetti S, Huber V et al (2012) Immune surveillance properties of human NK cell-derived exosomes. J Immunol 189, 2833-2842   DOI
47 Nolte-'t Hoen EN, Buschow SI, Anderton SM, Stoorvogel W and Wauben MH (2009) Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. Blood 113, 1977-1981   DOI
48 Lu Z, Zuo B, Jing R et al (2017) Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol 67, 739-748   DOI
49 Yong T, Zhang X, Bie N et al (2019) Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. Nat Commun 10, 3838   DOI
50 Matsumoto K, Morisaki T, Kuroki H et al (2004) Exosomes secreted from monocyte-derived dendritic cells support in vitro naive CD4+ T cell survival through NF-(kappa)B activation. Cell Immunol 231, 20-29   DOI
51 Besse B, Charrier M, Lapierre V et al (2016) Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology 5, e1071008   DOI
52 Simhadri VR, Reiners KS, Hansen HP et al (2008) Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One 3, e3377   DOI
53 Wang J, Wang Z, Mo Y, Zeng Z, Wei P and Li T (2015) Effect of hyperthermic CO2-treated dendritic cell-derived exosomes on the human gastric cancer AGS cell line. Oncol Lett 10, 71-76   DOI
54 Wahlgren J, Karlson Tde L, Glader P, Telemo E and Valadi H (2012) Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. PLoS One 7, e49723   DOI
55 Bebelman MP, Smit MJ, Pegtel DM and Baglio SR (2018) Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther 188, 1-11   DOI
56 Min H, Sun X, Yang X et al (2018) Exosomes derived from irradiated esophageal carcinoma-infiltrating T cells promote metastasis by inducing the epithelial-mesenchymal transition in esophageal cancer cells. Pathol Oncol Res 24, 11-18   DOI
57 Santos P and Almeida F (2021) Exosome-based vaccines: history, current state, and clinical trials. Front Immunol 12, 711565   DOI
58 Pitt JM, Charrier M, Viaud S et al (2014) Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol 193, 1006-1011   DOI
59 Chen DS and Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10   DOI
60 Saxena M, van der Burg SH, Melief CJM and Bhardwaj N (2021) Therapeutic cancer vaccines. Nat Rev Cancer 21, 360-378   DOI
61 Zitvogel L, Regnault A, Lozier A et al (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4, 594-600   DOI
62 Andre F, Chaput N, Schartz NE et al (2004) Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 172, 2126-2136   DOI
63 Pitt JM, Andre F, Amigorena S et al (2016) Dendritic cell-derived exosomes for cancer therapy. J Clin Invest 126, 1224-1232   DOI
64 Qazi KR, Gehrmann U, Domange Jordo E, Karlsson MC and Gabrielsson S (2009) Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood 113, 2673-2683   DOI
65 Segura E, Nicco C, Lombard B et al (2005) ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106, 216-223   DOI
66 Kalluri R (2016) The biology and function of exosomes in cancer. J Clin Invest 126, 1208-1215   DOI
67 Ciardiello C, Cavallini L, Spinelli C et al (2016) Focus on extracellular vesicles: new frontiers of cell-to-cell communication in cancer. Int J Mol Sci 17, 175   DOI
68 Fu W, Lei C, Liu S et al (2019) CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun 10, 4355   DOI
69 Thery C, Witwer KW, Aikawa E et al (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV 2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7, 1535750   DOI
70 Kahlert C and Kalluri R (2013) Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 91, 431-437   DOI
71 van Niel G, D'Angelo G and Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19, 213-228   DOI
72 Thery C, Duban L, Segura E, Veron P, Lantz O and Amigorena S (2002) Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 3, 1156-1162   DOI
73 Wei G, Jie Y, Haibo L et al (2017) Dendritic cells derived exosomes migration to spleen and induction of inflammation are regulated by CCR7. Sci Rep 7, 42996   DOI